D
Vanda Pharmaceuticals Inc.
VNDA
$4.92
-$0.03-0.61%
D
Sell
5/29/2024Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D from D- on 5/29/2024 due to an increase in the total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D from D- on 5/29/2024 due to an increase in the total return index and volatility index.
D
Sell
5/14/2024Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D- from D on 5/14/2024 due to a decline in the efficiency index, valuation index and growth index. Net income declined 72.75% from -$2.4M to -$4.15M, earnings per share declined from -$0.05 to -$0.0718, and EBIT declined 30.18% from -$7.09M to -$9.24M.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D- from D on 5/14/2024 due to a decline in the efficiency index, valuation index and growth index. Net income declined 72.75% from -$2.4M to -$4.15M, earnings per share declined from -$0.05 to -$0.0718, and EBIT declined 30.18% from -$7.09M to -$9.24M.
D
Sell
4/11/2024Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D from D- on 4/11/2024 due to an increase in the total return index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D from D- on 4/11/2024 due to an increase in the total return index.
D
Sell
3/27/2024Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D- from D on 3/27/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.0024 to -$0.05, net income declined 1,851.82% from $137 to -$2.4M, and operating cash flow declined 82.05% from -$2.05M to -$3.73M.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D- from D on 3/27/2024 due to a significant decline in the valuation index, efficiency index and growth index. Earnings per share declined from $0.0024 to -$0.05, net income declined 1,851.82% from $137 to -$2.4M, and operating cash flow declined 82.05% from -$2.05M to -$3.73M.
D
Sell
8/1/2023Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D from D+ on 8/1/2023 due to a decline in the growth index, solvency index and efficiency index. EBIT declined 243.06% from $2M to -$2.87M, operating cash flow declined 141.57% from $31.8M to -$13.22M, and earnings per share declined from $0.057 to $0.0265.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D from D+ on 8/1/2023 due to a decline in the growth index, solvency index and efficiency index. EBIT declined 243.06% from $2M to -$2.87M, operating cash flow declined 141.57% from $31.8M to -$13.22M, and earnings per share declined from $0.057 to $0.0265.
D
Sell
5/4/2023Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D+ from D on 5/4/2023 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 237.75% from $9.42M to $31.8M, and total capital increased 1.51% from $538.34M to $546.47M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D+ from D on 5/4/2023 due to a significant increase in the valuation index, efficiency index and growth index. Operating cash flow increased 237.75% from $9.42M to $31.8M, and total capital increased 1.51% from $538.34M to $546.47M.
D
Sell
4/11/2023Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D from D+ on 4/11/2023 due to a decline in the valuation index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D from D+ on 4/11/2023 due to a decline in the valuation index and volatility index.
D
Sell
3/24/2023Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D+ from D on 3/24/2023 due to an increase in the volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D+ from D on 3/24/2023 due to an increase in the volatility index.
D
Sell
3/8/2023Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D from D+ on 3/8/2023 due to a large decline in the valuation index, efficiency index and total return index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D from D+ on 3/8/2023 due to a large decline in the valuation index, efficiency index and total return index.
D
Sell
5/10/2022Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 5/10/2022 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.1202 to -$0.1146, EBIT declined 188.8% from $8.64M to -$7.67M, and operating cash flow declined 84.79% from $26.61M to $4.05M.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 5/10/2022 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.1202 to -$0.1146, EBIT declined 188.8% from $8.64M to -$7.67M, and operating cash flow declined 84.79% from $26.61M to $4.05M.
C
Hold
3/28/2022Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 3/28/2022 due to a decline in the total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 3/28/2022 due to a decline in the total return index and volatility index.
C
Hold
3/2/2022Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 3/2/2022 due to a decline in the volatility index, total return index and growth index. EBIT declined 20.18% from $10.82M to $8.64M, earnings per share declined from $0.1396 to $0.1202, and total revenue declined 2.96% from $70.1M to $68.02M.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 3/2/2022 due to a decline in the volatility index, total return index and growth index. EBIT declined 20.18% from $10.82M to $8.64M, earnings per share declined from $0.1396 to $0.1202, and total revenue declined 2.96% from $70.1M to $68.02M.
C
Hold
2/23/2022Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 2/23/2022 due to an increase in the volatility index and valuation index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 2/23/2022 due to an increase in the volatility index and valuation index.
C
Hold
2/7/2022Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 2/7/2022 due to a decline in the total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 2/7/2022 due to a decline in the total return index and volatility index.
C
Hold
12/17/2021Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 12/17/2021 due to an increase in the valuation index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 12/17/2021 due to an increase in the valuation index and volatility index.
C
Hold
11/30/2021Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 11/30/2021 due to a decline in the volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 11/30/2021 due to a decline in the volatility index.
C
Hold
11/12/2021Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 11/12/2021 due to a large increase in the valuation index, volatility index and total return index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 11/12/2021 due to a large increase in the valuation index, volatility index and total return index.
C
Hold
11/3/2021Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 11/3/2021 due to a decline in the valuation index, volatility index and efficiency index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 11/3/2021 due to a decline in the valuation index, volatility index and efficiency index.
C
Hold
10/8/2021Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 10/8/2021 due to an increase in the volatility index and total return index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 10/8/2021 due to an increase in the volatility index and total return index.
C
Hold
9/21/2021Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 9/21/2021 due to a decline in the volatility index and growth index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 9/21/2021 due to a decline in the volatility index and growth index.
C
Hold
4/20/2021Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 4/20/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 105.91% from $9.37M to $19.3M, net income increased 37.72% from $5.95M to $8.19M, and EBIT increased 34.99% from $7.74M to $10.45M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 4/20/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 105.91% from $9.37M to $19.3M, net income increased 37.72% from $5.95M to $8.19M, and EBIT increased 34.99% from $7.74M to $10.45M.
C
Hold
12/8/2020Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 12/8/2020 due to an increase in the volatility index, total return index and valuation index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 12/8/2020 due to an increase in the volatility index, total return index and valuation index.
C
Hold
11/23/2020Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 11/23/2020 due to an increase in the total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 11/23/2020 due to an increase in the total return index and volatility index.
D
Sell
8/28/2020Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 8/28/2020 due to a decline in the solvency index, total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 8/28/2020 due to a decline in the solvency index, total return index and volatility index.
C
Hold
8/13/2020Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 8/13/2020 due to a large increase in the growth index, efficiency index and volatility index. EBIT increased 7,436.8% from -$125 to $9.17M, operating cash flow increased 2,746.75% from -$907 to $24.01M, and net income increased 1,693% from $486 to $8.71M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 8/13/2020 due to a large increase in the growth index, efficiency index and volatility index. EBIT increased 7,436.8% from -$125 to $9.17M, operating cash flow increased 2,746.75% from -$907 to $24.01M, and net income increased 1,693% from $486 to $8.71M.
D
Sell
4/17/2020Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 4/17/2020 due to a decline in the volatility index, total return index and valuation index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 4/17/2020 due to a decline in the volatility index, total return index and valuation index.
C
Hold
3/16/2020Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 3/16/2020 due to a decline in the growth index and volatility index. Earnings per share declined from $1.84 to $0.079, and EBIT declined 60.56% from $10.76M to $4.24M.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 3/16/2020 due to a decline in the growth index and volatility index. Earnings per share declined from $1.84 to $0.079, and EBIT declined 60.56% from $10.76M to $4.24M.
C
Hold
11/25/2019Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 11/25/2019 due to a significant increase in the valuation index, efficiency index and volatility index. Net income increased 771.27% from $11.53M to $100.42M, and total capital increased 33.3% from $311.94M to $415.82M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 11/25/2019 due to a significant increase in the valuation index, efficiency index and volatility index. Net income increased 771.27% from $11.53M to $100.42M, and total capital increased 33.3% from $311.94M to $415.82M.
C
Hold
9/23/2019Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 9/23/2019 due to a decline in the total return index, valuation index and solvency index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 9/23/2019 due to a decline in the total return index, valuation index and solvency index.
C
Hold
8/2/2019Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from D+ on 8/2/2019 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 1,983.33% from -$612 to $11.53M, earnings per share increased from -$0.0116 to $0.21, and EBIT increased 574.13% from -$2.09M to $9.9M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from D+ on 8/2/2019 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 1,983.33% from -$612 to $11.53M, earnings per share increased from -$0.0116 to $0.21, and EBIT increased 574.13% from -$2.09M to $9.9M.
D
Sell
6/6/2019Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 6/6/2019 due to a decline in the volatility index and total return index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 6/6/2019 due to a decline in the volatility index and total return index.
C
Hold
5/7/2019Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 5/7/2019 due to a major decline in the growth index, total return index and volatility index. EBIT declined 122.81% from $9.15M to -$2.09M, earnings per share declined from $0.1958 to -$0.0116, and operating cash flow declined 36.82% from $15.26M to $9.64M.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 5/7/2019 due to a major decline in the growth index, total return index and volatility index. EBIT declined 122.81% from $9.15M to -$2.09M, earnings per share declined from $0.1958 to -$0.0116, and operating cash flow declined 36.82% from $15.26M to $9.64M.
C
Hold
3/12/2019Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 3/12/2019 due to a decline in the volatility index, total return index and valuation index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C from C+ on 3/12/2019 due to a decline in the volatility index, total return index and valuation index.
C
Hold
2/21/2019Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 2/21/2019 due to a noticeable increase in the valuation index, volatility index and growth index. Operating cash flow increased 75.56% from $8.69M to $15.26M, earnings per share increased from $0.13 to $0.1958, and EBIT increased 46.8% from $6.23M to $9.15M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C+ from C on 2/21/2019 due to a noticeable increase in the valuation index, volatility index and growth index. Operating cash flow increased 75.56% from $8.69M to $15.26M, earnings per share increased from $0.13 to $0.1958, and EBIT increased 46.8% from $6.23M to $9.15M.
C
Hold
11/8/2018Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 11/8/2018 due to a noticeable increase in the efficiency index, valuation index and total return index. Net income increased 55.52% from $4.61M to $7.17M, and total capital increased 4.04% from $251.27M to $261.42M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 11/8/2018 due to a noticeable increase in the efficiency index, valuation index and total return index. Net income increased 55.52% from $4.61M to $7.17M, and total capital increased 4.04% from $251.27M to $261.42M.
C
Hold
11/6/2018Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 11/6/2018 due to a noticeable decline in the total return index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 11/6/2018 due to a noticeable decline in the total return index.
C
Hold
10/2/2018Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 10/2/2018 due to an increase in the total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 10/2/2018 due to an increase in the total return index and volatility index.
C
Hold
9/17/2018Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 9/17/2018 due to a noticeable decline in the total return index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to C- from C on 9/17/2018 due to a noticeable decline in the total return index.
C
Hold
8/3/2018Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 8/3/2018 due to a large increase in the total return index, growth index and efficiency index. Operating cash flow increased 168.07% from $1.64M to $4.39M, EBIT increased 60.24% from $2.44M to $3.91M, and net income increased 50.39% from $3.07M to $4.61M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 8/3/2018 due to a large increase in the total return index, growth index and efficiency index. Operating cash flow increased 168.07% from $1.64M to $4.39M, EBIT increased 60.24% from $2.44M to $3.91M, and net income increased 50.39% from $3.07M to $4.61M.
C
Hold
5/17/2018Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 5/17/2018 due to a noticeable increase in the total return index, solvency index and valuation index. The quick ratio increased from 2.29 to 3.78.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 5/17/2018 due to a noticeable increase in the total return index, solvency index and valuation index. The quick ratio increased from 2.29 to 3.78.
D
Sell
4/16/2018Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 4/16/2018 due to a decline in the total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C- on 4/16/2018 due to a decline in the total return index and volatility index.
C
Hold
3/8/2018Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 3/8/2018 due to an increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.21 to 2.29.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 3/8/2018 due to an increase in the total return index, solvency index and volatility index. The quick ratio increased from 2.21 to 2.29.
D
Sell
10/25/2017Downgrade
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C on 10/25/2017 due to a substantial decline in the total return index.
Vanda Pharmaceuticals Inc. (VNDA) was downgraded to D+ from C on 10/25/2017 due to a substantial decline in the total return index.
C
Hold
10/10/2017Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 10/10/2017 due to an increase in the total return index and volatility index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C from C- on 10/10/2017 due to an increase in the total return index and volatility index.
C
Hold
8/4/2017Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 8/4/2017 due to a substantial increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.1722 to -$0.0343, EBIT increased 75.66% from -$7.91M to -$1.92M, and operating cash flow increased 57.81% from -$5.36M to -$2.26M.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to C- from D+ on 8/4/2017 due to a substantial increase in the growth index, total return index and solvency index. Earnings per share increased from -$0.1722 to -$0.0343, EBIT increased 75.66% from -$7.91M to -$1.92M, and operating cash flow increased 57.81% from -$5.36M to -$2.26M.
D
Sell
6/28/2017Upgraded
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D+ from D on 6/28/2017 due to a major increase in the efficiency index, total return index and solvency index.
Vanda Pharmaceuticals Inc. (VNDA) was upgraded to D+ from D on 6/28/2017 due to a major increase in the efficiency index, total return index and solvency index.
D
Sell
7/29/2016Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to D from D- on 7/29/2016 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2867 to -$0.1069, EBIT increased 61.61% from -$12.48M to -$4.79M, and operating cash flow increased 33.41% from -$4.9M to -$3.26M.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to D from D- on 7/29/2016 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2867 to -$0.1069, EBIT increased 61.61% from -$12.48M to -$4.79M, and operating cash flow increased 33.41% from -$4.9M to -$3.26M.
D
Sell
5/6/2016Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to D- from D on 5/6/2016 due to a decline in the efficiency index, volatility index and total return index. Total capital declined 7.53% from $133.03M to $123.01M.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to D- from D on 5/6/2016 due to a decline in the efficiency index, volatility index and total return index. Total capital declined 7.53% from $133.03M to $123.01M.
D
Sell
3/11/2016Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to D from D+ on 3/11/2016 due to a large decline in the volatility index, solvency index and total return index.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to D from D+ on 3/11/2016 due to a large decline in the volatility index, solvency index and total return index.
D
Sell
2/12/2016Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to D+ from C- on 2/12/2016 due to a significant decline in the valuation index, solvency index and growth index. Operating cash flow declined 92.66% from -$4.85M to -$356, and the quick ratio declined from 3.49 to 3.11.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to D+ from C- on 2/12/2016 due to a significant decline in the valuation index, solvency index and growth index. Operating cash flow declined 92.66% from -$4.85M to -$356, and the quick ratio declined from 3.49 to 3.11.
C
Hold
2/9/2016Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to C- from C on 2/9/2016 due to a large decline in the volatility index.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to C- from C on 2/9/2016 due to a large decline in the volatility index.
C
Hold
1/11/2016Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to C from B- on 1/11/2016 due to a large decline in the total return index and volatility index.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to C from B- on 1/11/2016 due to a large decline in the total return index and volatility index.
B
Buy
12/31/2015Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B- from C+ on 12/31/2015 due to an increase in the total return index, solvency index and valuation index.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B- from C+ on 12/31/2015 due to an increase in the total return index, solvency index and valuation index.
C
Hold
11/16/2015Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to C+ from B- on 11/16/2015 due to a decline in the volatility index and total return index.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to C+ from B- on 11/16/2015 due to a decline in the volatility index and total return index.
B
Buy
11/6/2015Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to B- from A- on 11/6/2015 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 140.09% from $12.1M to -$4.85M, and total capital declined 2.54% from $149.75M to $145.94M.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to B- from A- on 11/6/2015 due to a significant decline in the efficiency index, growth index and total return index. Operating cash flow declined 140.09% from $12.1M to -$4.85M, and total capital declined 2.54% from $149.75M to $145.94M.
A
Buy
8/13/2015Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to A- from B+ on 8/13/2015 due to an increase in the volatility index.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to A- from B+ on 8/13/2015 due to an increase in the volatility index.
B
Buy
7/31/2015Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B+ from B on 7/31/2015 due to a large increase in the valuation index, growth index and solvency index. Operating cash flow increased 117.84% from $5.56M to $12.1M, and total revenue increased 24.52% from $22.15M to $27.58M.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B+ from B on 7/31/2015 due to a large increase in the valuation index, growth index and solvency index. Operating cash flow increased 117.84% from $5.56M to $12.1M, and total revenue increased 24.52% from $22.15M to $27.58M.
B
Buy
6/10/2015Downgrade
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to B from B+ on 6/10/2015 due to a decline in the valuation index.
Vanda Pharmaceuticals, Inc. (VNDA) was downgraded to B from B+ on 6/10/2015 due to a decline in the valuation index.
B
Buy
5/26/2015Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B+ from B on 5/26/2015 due to a noticeable increase in the volatility index.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B+ from B on 5/26/2015 due to a noticeable increase in the volatility index.
B
Buy
5/11/2015Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B from C on 5/11/2015 due to a significant increase in the valuation index, efficiency index and growth index. Total revenue increased 44.12% from $15.37M to $22.15M, and EBIT increased 40.56% from -$7.32M to -$10.29M.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to B from C on 5/11/2015 due to a significant increase in the valuation index, efficiency index and growth index. Total revenue increased 44.12% from $15.37M to $22.15M, and EBIT increased 40.56% from -$7.32M to -$10.29M.
C
Hold
3/13/2015Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to C from D+ on 3/13/2015 due to a substantial increase in the valuation index, efficiency index and solvency index. Total capital increased 15,028.6% from $1.06M to $160.82M, and the quick ratio increased from 1.54 to 17.14.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to C from D+ on 3/13/2015 due to a substantial increase in the valuation index, efficiency index and solvency index. Total capital increased 15,028.6% from $1.06M to $160.82M, and the quick ratio increased from 1.54 to 17.14.
D
Sell
8/11/2014Upgraded
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to D+ from D on 8/11/2014 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 53.38% from -$23.9M to -$36.67M, and total revenue increased 18.8% from $9.14M to $10.86M.
Vanda Pharmaceuticals, Inc. (VNDA) was upgraded to D+ from D on 8/11/2014 due to a significant increase in the growth index, total return index and volatility index. Operating cash flow increased 53.38% from -$23.9M to -$36.67M, and total revenue increased 18.8% from $9.14M to $10.86M.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
